切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2017, Vol. 06 ›› Issue (06) : 442 -446. doi: 10.3877/cma.j.issn.2095-3224.2017.06.001

所属专题: 文献

指南与共识

结直肠癌术中腹腔化疗专家意见(2017版)
中国医师协会结直肠肿瘤专业委员会1   
  1. 1. 100021 北京,国家癌症中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科
  • 收稿日期:2017-08-27 出版日期:2017-12-25
  • 基金资助:
    国家自然科学基金面上项目(No.81572930); 中国医学科学院肿瘤医院学科带头人奖励基金(No.RC2016003); 国家重点研发计划精准医学研究专项(No.2016YFC0905300); 中国医学科学院医学与健康科技创新工程项目(No.2016-I2M-1-001)

Chinese expert opinion on intraoperative chemotherapy for colorectal cancer (2017 edition)

Colorectal Cancer Committee of Chinese Medical Doctor Association1   

  • Received:2017-08-27 Published:2017-12-25
  • About author:
    Corresponding author: Wang Xishan, Email:
引用本文:

中国医师协会结直肠肿瘤专业委员会. 结直肠癌术中腹腔化疗专家意见(2017版)[J/OL]. 中华结直肠疾病电子杂志, 2017, 06(06): 442-446.

Colorectal Cancer Committee of Chinese Medical Doctor Association. Chinese expert opinion on intraoperative chemotherapy for colorectal cancer (2017 edition)[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(06): 442-446.

结直肠癌是我国最常见的恶性肿瘤之一,其发病率居高不下,腹腔种植转移作为常见转移方式,是治疗失败的常见原因之一。腹腔化疗将化疗药物注入腹腔,直接作用于腹腔内种植和脱落的癌细胞,维持腹腔内较高的有效药物浓度,延长作用时间,是治疗和预防结直肠癌腹腔种植转移的重要方法。腹腔化疗的方案种类繁多,用量及浓度也差别较大,尚无统一标准规范。为了规范结直肠癌术中腹腔化疗适应证及禁忌证的选择、规范腹腔灌注化疗药物的用法用量及术后监测指标等,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌术中腹腔化疗专家意见》,旨在规范结直肠癌术中腹腔化疗方法,提高我国结直肠肿瘤的整体诊治水平,延长结直肠癌患者生存时间并改善生活质量。

Colorectal cancer is one of the most common malignancies in China. The incidence of colorectal cancer is high, and intraperitoneal implantation is one of the common causes of treatment failure. Intraperitoneal chemotherapy, which directly injects the chemotherapeutic drugs into the abdominal cavity to inhibit the intraperitoneal implantation and shedding of cancer cells, improve the intraperitoneal effective drug concentration, and prolong the effect of time, is one of the important methods of treatment and prevention of colorectal cancer intraperitoneal transplantation. Because of many various programs, there is no uniform standard in the amount and concentration of drugs. Therefore, in order to regulate the colorectal cancer intraoperative chemotherapy indications and contraindications, regulate the usage of intraperitoneal injection of chemotherapy drugs and the monitoring indicators, the relevant experts from Colorectal Cancer Committee of Chinese Medical Doctor Association developed ″Colorectal cancer intraoperative chemotherapy expert advice″. It aimed at regulate the method of colorectal cancer intraperitoneal chemotherapy, improve the overall prevention of colorectal peritoneal metastasis in China, extend the survival time of patients with colorectal cancer and improve the quality of life.

1
Chen WZR,Baade PD,Zhang S, et al. Cancer Statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66 (2): 115-132.
2
Cunningham D,Atkin W,Lenz HJ, et al. Colorectal cancer [J]. Lancet, 2010, 375 (9719): 1030-1047.
3
al JDFSLCe. Peritoneal careinomatosis from colorectal cancer [J]. Br J Surg, 2002, 89 (12): 1545-1550.
4
何振华,张森,宋现青. 结直肠癌腹膜种植转移的相关因素分析 [J]. 中国肿瘤临床, 2013, 40 (2): 107-110.
5
Kim MS CC,Yoo S,Cho C, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma [J]. Jpn J Clin Oncol, 2008, 38 (10): 695-700.
6
Fisher B GN,Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [J]. Cancer Res, 1983, 43: 1488-1492.
7
Elias D,Glehen O,Pocard M, et al. A comparative study of complete cytoreduetive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and no pseudomyxoma appendix [J]. Ann Surg, 2010, 251 (5): 896-901.
8
Sugarbaker PH. Carcinomatosis from gastrointestinal cancer [J]. Ann Med, 2004, 36 (1): 9-22.
9
Seymour MT,Trigonis I,Finan PJ, et al. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer [J]. Eur J Surg Oncol, 2008, 34 (4): 403-409.
10
姜福全,王强,蔡清萍. 氟尿嘧啶腹腔内缓释化疗的家兔门静脉血药浓度测定 [J]. 外科理论与实践, 2006, 11(6): 524-527.
11
Xue Bai,Bo Yu,Junfeng, et al. Effects of lobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line [J]. Chinese-German Journal of Clinical Oncology, 2010, 9 (1): 36-39.
12
王琳,谢贤和,陈俊民. 含洛铂联合化疗方案治疗晚期消化道恶性肿瘤Meta分析 [J]. 山东医药, 2013, 53(34): 48-50.
13
Laboratories A. Lobaplatin:D 19466 [J]. Drugs RD, 2003, 4(6): 369-372.
14
Bleiberg H,Vandebroek A,Deleu I, et al. A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer [J]. Acta Gastroenterol Belg, 2012, 75 (1): 14-21.
15
Kim R PG,Shridhar R,Hoffe SE, et al. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma [J]. Radiother Oncol, 2016, 118 (2): 382-386.
16
Archer S,Gray B. IntraperitoneaI 5-fIuorouraciI infusion for treatment of both peritoneaI and Iiver micrometastases [J]. Surgery, 1992, 108(3): 502-507.
17
Vaillant JC NB,Deuffic S,Arnaud JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial [J]. Ann Surg, 2000, 231 (4): 449-456.
18
Yasui H1 MK,Shimada Y,Tsuji A, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study [J]. J Cancer Res Clin Oncol, 2015, 14 (1): 153-160.
19
HiIIan K,NoroIinger B,BaIIet F, et aI. The heaIing of coIonic anastomoses after earIy intraperitoneaI chemotherapy: an experimentaI study in rats [J]. J Surg Res, 1988, 44 (2): 166-171.
20
肖军,金钦文,覃字周. 结直肠癌根治术中植入缓释氟尿嘧啶安全性及疗效荟萃分析 [J]. 中华普通外科杂志, 2011, 26(4): 358-359.
21
Zhao P,Ding Z,Tang L, et al. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer [J]. World J Surg Oncol, 2014, 12 (1): 1-7.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[4] 施烨鑫, 马翔, 鲁明, 夏青城, 王鹏超, 宋青雨, 赵庆洪. 腹腔镜下结直肠肿瘤定位研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 463-466.
[5] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[6] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[7] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[8] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[9] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[10] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[11] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[12] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[13] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[14] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[15] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?